


FILE 'MEDLINE' ENTERED AT 19:02:10 ON 23 FEB 2001

L1	1159 S OSTEOPONTIN
L2	20455 S ADENOVIR?
L3	4 S L1 AND L2
L4	52594 S IMMUNE RESPONS?
L5	2 S L1 AND L4
L6	1278 S ETA-1 OR OPN OR OSTEOPONTIN
L7	2 S L6 AND L4
L8	4 S L6 AND L2
L9	0 S L4 AND L8
L10	170028 S IMMUNIZ? OR VACCIN?
L11	1 S ADENIVIR?
L12	20455 S ADENOVIR?
L13	1360 S L10 AND L12
L14	72346 S VECTOR?
L15	3993 S L12 AND L14
L16	339 S L15 AND L10
L17	28310 S MHC?
L18	4 S L16 AND 17

TITLE: Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- **adenovirus** gene transfer **vector**.
 AUTHOR: Harvey B G; Worgall S; Ely S; Leopold P L; Crystal R G
 CORPORATE SOURCE: Department of Medicine, Weill Medical College of Cornell University-New York Presbyterian Hospital, NY 10021, USA.
 CONTRACT NUMBER: P01 HL51746 (NHLBI)
 SOURCE: M01RR00102 (NCRR)
 HUMAN GENE THERAPY, (1999 Nov 20) 10 (17) 2823-37.
 Journal code: A12. ISSN: 1043-0342.
 PUB. COUNTRY: United States
 (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200002
 ENTRY WEEK: 20000204

AB In animals, Ad-mediated gene transfer initiates anti-Ad host immune responses that vary, depending on **vector** design, dose, host, and transgene. To begin to understand whether the anti-Ad **vector** responses in humans simulate those in animals, Ad(GV)CD.10, an E1-E3- Ad5 **vector** encoding the E. coli cytosine deaminase gene, was administered by the intradermal route to six normal individuals (8 x 10(7) to 8 x 10(9) particle units, each dose administered to two sites; n = 2 per group). No adverse events were observed. Polymerase chain reaction/Southern analysis demonstrated **vector** genome in the skin through 28 days in all individuals except one of two at the lowest dose. Local induration, independent of **vector** dose and baseline systemic anti-Ad5 neutralizing antibodies, developed in all subjects (6 to 17 mm, peak by day 3). Biopsies revealed a mild to moderate T cell (CD3+, CD4+, CD8+), B cell, and macrophage infiltrate at day 3, all decreased by day 28. Langerhans cells accumulated primarily in the papillary dermis. The day 3 cellular response was dose independent. On day 28, CD4+ and CD8+ T lymphocytes and macrophages showed dose dependency. There was minimal systemic Ad5-specific lymphocyte proliferation induced by Ad **vector** administration in three individuals studied, and no Ad5-specific cytotoxic T lymphocytes (evaluated in two subjects) could be detected. Thus, intradermal administration of an E1-E3- Ad **vector** to normal subjects induces mild/moderate local cellular responses, even in Ad-immunized individuals. These observations provide a baseline to determine if these human anti-Ad **vector** host responses can be circumvented by using "stealth" **vectors** and/or immunosuppression.

=> d his



☒ L34: (0) L28 and L31
☒ L37: (79002) foreign or n
☒ L40: (21105) antigen?
☒ L43: (6165) L37 and L40
☒ L46: (2) L43 and L28
☒ L49: (51938) vector?
☒ L52: (5529) L2 and L40

Search

DBs:

☐ Plurals ☐ Synonyms

Default operator:

☒ Highlight all hit terms initially

☒ BRS form

☒ IS&R form

☒ Image


☒ Text

	U	1	Document ID	Issue Date	Pages	Title	Current OR	Current XRef	R
1	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6143871 A	20001107	25	IL-13 and IL-4 binding polypeptides	530/351	314/2 ; 435/69.1	
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6124436 A	20000926		Purified mammalian monocyte antigens and related	530/387.1	435/326 ; 435/331	
3	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6106832 A	20000822		Treatment of individuals exhibiting defective CD40L	424/134.1	424/184.1 ; 424/192.1	
4	<input type="checkbox"/>	<input type="checkbox"/>	US 6087329 A	20000711	61	CD40 ligand polypeptide	514/8	514/2 ; 514/885	
5	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6069229 A	20000530	41	Mammalian proteinases; oxidoreductases; related	530/300	435/252.3 ; 435/320.1	
6	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6030830 A	20000229	41	Immunoglobulin trans-spliced transcripts and uses thereof	435/320.1	536/23.1 ; 536/24.1	
7	<input type="checkbox"/>	<input type="checkbox"/>	US 5981724 A	19991109	65	DNA encoding CD40 ligand, a cytokine that binds CD40	536/23.5	435/252.3 ; 435/320.1	
8	<input type="checkbox"/>	<input type="checkbox"/>	US 5961974 A	19991005	59	Monoclonal antibodies to CD40 ligand, pharmaceutical	424/154.1	424/130.1 ; 424/141.1	
9	<input type="checkbox"/>	<input type="checkbox"/>	US 5962406 A	19991005	64	Recombinant soluble CD40 ligand polypeptide and	514/8	514/12 ; 514/2	
10	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 5945513 A	19990831	29	Fusion proteins comprising gp39 and CD8	530/387.3	424/134.1 ; 424/192.1	
11	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 5910417 A	19990608	29	Regulation of cytokine production in a	435/7.2	435/7.1 ; 436/501	

☒ Hits ☒ Details

Ready

NUM




Search List Browse Queue Clear

DBs ☒ USPAT:IBM TDE ☐ Plurals ☐ Synonyms

Default operator: ☐ OR ☒ Highlight all hit terms initially

L52 and L4

 BRS form
  ISR form
  Image
  Text

Failed

... (0) (T or B) with cell?

	U	1	Document ID	Issue Date	Pages	Title	Current OR	Current XRef	R
1	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6143871 A	20001107	25	IL-13 and IL-4 binding polypeptides	530/351	314/2 ; 435/69.1	
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 6124436 A	20000926		Purified mammalian monocyte	530/387.1	435/326	

 Hits
 Details

Ready

NUM: